The MONALEESA-7 trial involved women with HR-positive/HER2-negative, advanced breast cancer treated with ovarian function suppression and oral endocrine therapy with ribociclib or placebo: median progression-free survival of 23.8 months in the ribociclin arm and 13 months in the placebo arm [359]. Here, ERBB2 is linked to breast carcinoma.